Noshin Noorjahan

[Atherosclerosis] The authors review recent metabolomics studies in liver tissue from human MASLD patients, which have predominately focused on lipid metabolism, but also include bile acid, tricarboxylic acid cycle, and branched chain amino acid metabolism.

[American Liver Foundation] American Liver Foundation announced that Dr. Jacquelyn Maher is the winner of its 2024 Distinguished Scientific Achievement Award for her research contributions regarding NAFLD and mechanisms of liver cell toxicity.

[Acta Pharmacologica Sinica] Researchers investigated the beneficial effects of chikusetsusaponin IVa (CHS) on metabolic dysfunction steatotic liver disease (MASLD) and the underlying mechanisms. MAFLD mouse model was established by the high-fat diet for 6 weeks and then were treated with CHS for another 8 weeks.

[Molecular Biology Reports] Investigators evalurate a variety of breast cancer (BC) studies performed on organoid culture systems. Additionally, they report the potential of using organoid models in BC translational research, especially in immunotherapy, drug screening, and precision medicine.

[JNCI-Journal of The National Cancer Institute] Investigators hypothesized that metformin could benefit obese and overweight patients with NSCLC. They retrospectively analyzed two clinical cohorts and employed complementary mouse models to test their hypothesis. One cohort included NSCLC patients with overweight BMI and non-overweight BMI who underwent lobectomy.

[Nature Immunology] Researchers showed that, while STAT3 deletion restricted primary tumor growth, it paradoxically enhanced metastatic spread by promoting immune evasion.